Regulatory FDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial Pharmaceutical TechnologyREGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.Rare DiseaseRead full story pharminent August 25, 2026 (Last updated: August 25, 2026) Pharmaceutical Technology REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II. Rare Disease Read full story Post navigation Previous: Genentech Licenses Hanmi’s Muscle-Sparing Obesity Drug in Deal Worth Up to $2.3 BillionNext: FDA greenlights Roche’s biomarker blood test for Alzheimer’s Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026